在心力衰竭中降低抗氧化剂高密度脂蛋白功能,并保留喷射分数
Benjamin Sasko1,2,3, Theodoros Kelesidis4, Sawa Kostin5
1Ruhr-University of Bochum, Medical Department II, Marien Hospital Herne, Bochum, Germany. b.sasko@uk-brandenburg.de.
概括
降低HDL抗氧化功能与心力衰竭与保留射出分数 (HFpEF) 有关. 这一发现表明,改善HDL功能可能是早期HFpEF治疗的潜在治疗目标.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 是一个日益严重的全球健康问题,由于心血管风险因素,西方人口的患病率越来越高.
- 氧化应激和炎症是心力衰竭病理生理学的关键贡献者,心力衰竭具有保存的喷射分数 (HFpEF).
- 之前的研究表明,功能障碍的高密度脂蛋白 (HDL) 和高血压之间存在联系,但氧化HDL在HFpEF中的特定作用尚不清楚.
研究的目的:
- 研究HDL抗氧化功能降低与HFpEF存在之间的关联.
- 确定氧化HDL水平是否是怀疑心力衰竭的患者中HFpEF的独立预测因子.
主要方法:
- 一项涉及366名疑似心力衰竭患者的横截式观察性研究.
- 评估HDL抗氧化功能,使用无细胞生物化学测定测量HDL脂类过氧化物含量 (HDLox),通过HDL-C水平 (nHDLox) 正常化.
- 统计分析包括多变量模型来识别HFpEF的独立预测因素,调整各种临床和生化因素.
主要成果:
- 与没有心力衰竭的患者相比,HFpEF患者的nHDLox平均相对水平显著更高.
- 在基本和完整的多变量模型中,nHDLox被确定为HFpEF的独立预测因子 (p < 0.05).
- 在nHDLox的1-SD增加与HFpEF风险增加67%相关 (p = 0.02).
结论:
- 在被诊断为HFpEF的患者中,HDL抗氧化功能明显降低.
- 向和改善HDL功能为早期治疗心力衰竭提供了一个有希望的治疗策略.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314